Dimerix Limited (AU:DXB)
ASX:DXB
Want to see AU:DXB full AI Analyst Report?
Top Page
Dimerix Limited
(Sydney:DXB)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.20
▼(-49.25% Downside)
Action:Reiterated
Date:06/19/26
The score is primarily weighed down by weak financial quality (persistently negative margins, very negative ROE, and sharply declining free cash flow growth) despite strong revenue growth and low leverage. Technicals add pressure with the stock trading below key longer-term moving averages and a negative MACD, while valuation is constrained by losses (negative P/E) and no dividend yield data.
Positive Factors
Revenue Growth
Sustained top-line expansion (70% growth) demonstrates commercial traction or progress in near-term revenue drivers. Durable revenue growth increases optionality for funding R&D, supports partnerships, and reduces reliance on capital markets during multi-quarter clinical development.
Negative Factors
Negative Profitability
Consistent negative margins reflect structural cost and operational inefficiencies relative to revenue. Over the medium term, persistent operating losses can exhaust cash reserves or necessitate dilutive financing unless the company meaningfully improves margins or secures non-dilutive funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained top-line expansion (70% growth) demonstrates commercial traction or progress in near-term revenue drivers. Durable revenue growth increases optionality for funding R&D, supports partnerships, and reduces reliance on capital markets during multi-quarter clinical development.
Read all positive factors
Dimerix Limited (DXB) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$132.09M
Dividend YieldN/A
Average Volume (3M)1.47M
Price to Earnings (P/E)―
Beta (1Y)2.52
Revenue Growth1219.92%
EPS Growth38.88%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding600,396,800
10 Day Avg. Volume1,720,426
30 Day Avg. Volume1,468,144
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)24.09
Price to Sales (P/S)256.86
P/FCF Ratio8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$18.30M
Dimerix Limited Business Overview & Revenue Model
Company Description
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candid...
How the Company Makes Money
null...
Dimerix Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
40
Negative
Cash Flow
50
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.42M | 1.25M | 583.48K | 36.79K | 6.46M | 4.44M |
| Gross Profit | 5.30M | 1.25M | 583.48K | 36.79K | 6.41M | 4.39M |
| EBITDA | -40.31M | -36.22M | -24.96M | -22.68M | -16.47M | -10.02M |
| Net Income | -16.31M | -13.25M | -17.07M | -13.80M | -10.49M | -6.37M |
Balance Sheet | ||||||
| Total Assets | 64.56M | 91.18M | 32.08M | 17.76M | 16.50M | 9.42M |
| Cash, Cash Equivalents and Short-Term Investments | 38.49M | 68.28M | 22.14M | 7.99M | 9.63M | 5.25M |
| Total Debt | 33.42K | 97.48K | 149.68K | 5.96M | 73.10K | 5.09M |
| Total Liabilities | 66.24M | 77.80M | 13.89M | 11.79M | 2.07M | 7.95M |
| Stockholders Equity | -1.68M | 13.38M | 18.19M | 5.96M | 14.42M | 1.47M |
Cash Flow | ||||||
| Free Cash Flow | 11.43M | 39.03M | -7.02M | -12.73M | -13.45M | -6.47M |
| Operating Cash Flow | 11.44M | 39.05M | -7.00M | -12.73M | -13.44M | -6.46M |
| Investing Cash Flow | -10.56K | -21.01K | -15.80K | -2.30K | -10.61K | 4.38K |
| Financing Cash Flow | 6.38M | 7.42M | 21.17M | 11.07M | 17.69M | 3.83M |
Dimerix Limited Technical Analysis
Neutral
0.40
Price Trends
0.24
Negative
0.32
Negative
0.42
Negative
Market Momentum
>-0.01
Negative
49.56
Neutral
60.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:DXB, the sentiment is Neutral. The current price of 0.4 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.24, and below the 200-day MA of 0.42, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.56 is Neutral, neither overbought nor oversold. The STOCH value of 60.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:DXB.
Dimerix Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$512.85M | 15.34 | 13.29% | 0.38% | 5.17% | -16.14% | |
54 Neutral | AU$470.57M | -44.18 | -47.44% | ― | ― | -15.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$84.61M | -10.14 | -40.65% | ― | -100.00% | -11.11% | |
43 Neutral | AU$132.09M | -7.61 | -278.87% | ― | 1219.92% | 38.88% | |
41 Neutral | AU$208.27M | -14.73 | -44.80% | ― | 49.03% | -232.68% | |
40 Underperform | AU$76.63M | -0.89 | -69.20% | ― | ― | -73.11% |
* Healthcare Sector Average
AU:DXB
Dimerix Limited
0.21
-0.34
-62.04%
AU:CUV
Clinuvel Pharmaceuticals
9.95
-0.02
-0.21%
AU:OCC
Orthocell Ltd
0.75
-0.34
-31.02%
AU:IMM
Immutep Ltd
0.05
-0.18
-77.39%
AU:RAC
Race Oncology Ltd.
2.38
1.16
95.08%
AU:ALA
Arovella Therapeutics Limited
0.07
-0.03
-29.00%
Dimerix Limited Corporate Events
Dimerix Strikes Major Asian Licensing Deal for Phase 3 Kidney Drug DMX-200
Jun 16, 2026
Dimerix has signed an exclusive licensing agreement granting Everest Medicines rights to commercialise its Phase 3 kidney drug candidate DMX-200 for all indications, including focal segmental glomerulosclerosis, across Greater China, South Korea a...
Dimerix Highlights ACTION3 Trial De-Risking and Commercial Potential for DMX-200
Apr 28, 2026
Dimerix Limited has released an updated investor presentation and video detailing progress on its Phase 3 ACTION3 trial of lead kidney disease candidate DMX-200, following blinded statistical analysis results. The materials outline the companyR...
Dimerix Confirms Strong Statistical Power and Refines Strategy for Phase 3 FSGS Trial
Apr 27, 2026
Dimerix has confirmed that its Phase 3 ACTION3 trial of DMX-200 in FSGS remains statistically well powered, with a blinded external review showing more than a 90% chance of demonstrating a significant treatment effect on the primary endpoint of pr...
Dimerix to Court Singapore Investors With Update on Phase 3 Kidney Drug
Apr 9, 2026
Dimerix Limited has announced an updated venue and details for an investor lunch briefing in Singapore on 20 April 2026, where CEO and Managing Director Dr Nina Webster will outline progress of the global ACTION3 Phase 3 trial in FSGS kidney disea...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.